Sysmex (OTCMKTS:SSMXY) Shares Gap Down – What’s Next?

Shares of Sysmex Corporation ADR (OTCMKTS:SSMXY) gapped down before the market opened on Tuesday . The stock had previously closed at $9.78, but opened at $9.2501. Sysmex shares last traded at $9.5870, with a volume of 3,567 shares.

Analyst Upgrades and Downgrades

Separately, The Goldman Sachs Group raised shares of Sysmex from a “hold” rating to a “buy” rating in a research report on Thursday, October 9th. One investment analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, Sysmex presently has an average rating of “Moderate Buy”.

Sysmex Stock Down 1.9%

The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.49 and a current ratio of 3.34. The firm has a 50 day simple moving average of $9.75 and a two-hundred day simple moving average of $11.97. The stock has a market cap of $6.04 billion, a P/E ratio of 19.19 and a beta of 1.13.

Sysmex (OTCMKTS:SSMXY) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $0.16 EPS for the quarter, meeting analysts’ consensus estimates of $0.16. The company had revenue of $826.60 million for the quarter, compared to analyst estimates of $880.80 million. Sysmex had a return on equity of 9.86% and a net margin of 9.32%. Equities research analysts predict that Sysmex Corporation ADR will post 0.57 earnings per share for the current year.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.